Thanks, operator.
third on progress During made fiscal financial our commercialization, of the we objectives. development and XXXX, significant quarter product
provide balance importantly, secured This recent on August would the update to improvements and launch, diligence a the ablation process will the strategic partner like I facility $X potential company X, distribution new commercial credit limited we commercial our system. the intended raise to capital OneRF for complete release into private of OneRF completed OneRF to ablation First, also placement and allow limited for million development the complete the a the expand system.
On an product and with $X.XX a sheet million entered indication agreement. ablation with a most
device. electrical activity tissue of an the FDA-cleared with recording use this utilizing intended for nervous is reminder, both ablation technology first a the same As and system
performed OneRF implanted centers patients, XX across launch have RF X continue and and make XX product We limited than on progress ablations the patients. X to with more now
process also from OneRF additional product completed. quotation electrodes an We centers. sEEG transition manufacturing our Evo been sales strictly electrodes with XX has offering of The initiated diagnostic the have also to
margins the of forward. to of also burn the drive electrodes the are to addition, RF monthly development expected OneRF product transition going generator In completion and our cash and in improvements
our system, an the Regarding we directly. medical with ablation as customary OneRF The device distribution undisclosed But for definitive are recently term sheet to closing company the the ablation partnership a and and due of global OneRF we is distribute conditions. product the sheet announced, to diligence nonbinding system. technology currently negotiation other and is have execution term we documentation, signed distributing subject
using code centers and hospital to effective a and We processing October inpatient Services, OneRF hospitals that are granted support X, also for the of XXXX, will by system happy OneRF approved ablation the and be procedure. new otherwise are The procedures procedure. accurate and performed data that new the of claims allows collection report for ICD-XX-PCS Medicaid for Medicare reporting as the CMS, to known reimbursement ablation code
In brain, to also indications addition to RF to we pain. planning other are generator ablation leverage treat ablation for in the our
investment XXXX. hospitals, purchasing value in multiple generator our next provide be believe our OneRF our system will indications a in decisions. the consideration application which in ablation for are developing We year added targeting calendar early We hospital can having critical to leverage FDA to the and
platform great technology thin-film programs, with our product also stimulation. and leveraging progress spinal making our We are drug development electrode cord for delivery
system based believe therapeutic with brain conditions gene cell as biopharmaceutical variety stem timelines helpful delivery the platform the to variety potential sEEG deliver pharmacologic sEEG a our drug delivery about therapies well the could in and be of agents, a reducing therapies. for neurological be being studies We to drug continue for cost and development the clinical where drugs capability for existing sEEG leverage accelerating we excited including and technology can impact.
We treated our as of to based with drug monitoring therapies of
the system. strategic multiple drug partners quarter, our for discussions During sEEG delivery we based with in have active past been
making suffering from percutaneous designed and program our stimulation substantial back neck We spinal patients are progress paddle also with lead for pain. treat in to use cord
freeze calendar to fiscal to year of novel product would results. to to further the provide that are with of of Ron by call design commercialization the strategic review year be discussions the over now XXXX expect interested initiate Ron? McClurg our a may We and third quarter end planning development in potential funding partners to technology.
I and like this turn
